-- Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q2 Revenue $18.9M, vs. Street Est of $23.2M
4:33PM ET 8/11/2022 MT Newswires...
...
...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Fortress Biotech (FBIO) on Friday said it appointed David Jin as chief financial officer, effective Aug. 16. Jin will also continue serving as the...
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively,...
Address | 1111 Kane Concourse Bay Harbor Islands, Florida 33154 |
Phone | +1.781.652.4500 |
Number of Employees | 88 |
Recent SEC Filing | 08/11/2022![]() |
Chairman, President & Chief Executive Officer | Lindsay Allan Rosenwald |
Chief Financial Officer, Secretary & Treasurer | Robyn M. Hunter |
Senior Vice President-Biologics Operations | George C. Avgerinos |
Director & Vice Chairman-Strategic Development | Michael Sean Weiss |
Price Open | $1.27 |
Previous Close | $1.27 |
52 Week Range | $0.77 - 3.81 |
Market Capitalization | $134.7 M |
Shares Outstanding | 107.7 M |
Sector | Health Technology |
Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/21/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | N/A |
Earnings per Share | -$1.06 |
Beta vs. S&P 500 | N/A |
Revenue | $26.9 M |
Net Profit Margin | -108.87% |
Return on Equity | -95.07% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |